litlas
Log inCreate account

Nadia Harbeck

Active 1993–2025

385
Papers
79,331
Citations
132
h-index
352
i10-index

Citations

Citations per year for Nadia Harbeck1926: 1 citations1964: 3 citations1971: 3 citations1974: 2 citations1981: 1 citations1991: 1 citations1993: 4 citations1994: 8 citations1995: 9 citations1996: 8 citations1997: 12 citations1998: 17 citations1999: 28 citations2000: 29 citations2001: 56 citations2002: 61 citations2003: 71 citations2004: 110 citations2005: 77 citations2006: 70 citations2007: 103 citations2008: 155 citations2009: 161 citations2010: 217 citations2011: 218 citations2012: 241 citations2013: 224 citations2014: 255 citations2015: 280 citations2016: 417 citations2017: 501 citations2018: 553 citations2019: 2,072 citations2020: 2,870 citations2021: 3,558 citations2022: 3,449 citations2023: 3,089 citations2024: 4,697 citations2025: 2,507 citations2026: 85 citations1927–1963: no citations, so these years are not shown1965–1970: no citations, so these years are not shown1972–1973: no citations, so these years are not shown1975–1980: no citations, so these years are not shown1982–1990: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,365 citing papers, 19.5% of this breakdownChina: 3,346 citing papers, 12.2% of this breakdownItaly: 1,815 citing papers, 6.6% of this breakdownGermany: 1,573 citing papers, 5.7% of this breakdownUnited Kingdom: 1,419 citing papers, 5.2% of this breakdownFrance: 1,137 citing papers, 4.1% of this breakdownSpain: 1,085 citing papers, 3.9% of this breakdownCanada: 871 citing papers, 3.2% of this breakdownSwitzerland: 754 citing papers, 2.7% of this breakdownBelgium: 726 citing papers, 2.6% of this breakdownAustralia: 712 citing papers, 2.6% of this breakdownJapan: 688 citing papers, 2.5% of this breakdown
0%19.5%Other 29.2%

Institutions

Fields

  • Medicine56%
  • Biochemistry, Genetics and Molecular Biology34.8%
  • Immunology and Microbiology2.3%
  • Computer Science1.6%
  • Engineering1.3%
  • Materials Science0.8%
  • Other3.2%

Topics

  • Breast Cancer Treatment Studies8%
  • HER2/EGFR in Cancer Research6.7%
  • Advanced Breast Cancer Therapies6.5%
  • Cancer Immunotherapy and Biomarkers3.8%
  • Cancer Cells and Metastasis2.5%
  • Cancer Treatment and Pharmacology2.4%
  • Other70.1%

Coauthors

All papers

Open in search
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

    Authors: Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron - New England Journal of Medicine 2022 cited by 2,548

  2. Pembrolizumab for Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy - New England Journal of Medicine 2020 cited by 3,116

  3. Breast cancer

    Authors: Nadia Harbeck, Frédérique Penault‐Llorca, Javier Cortés, Michael Gnant, Nehmat Houssami, Philip Poortmans, Kathryn J. Ruddy, Janice Tsang, Fátima Cardoso - Nature Reviews Disease Primers 2019 cited by 2,941

  4. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 1,145

  5. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Authors: Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck - Annals of Oncology 2021 cited by 1,367

  6. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    Authors: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, F. Vidal Luis, Gomez Abuin Gonzalo, Diego Kaen, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Sally Baron-Hay, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Andrea Gombos, Donatienne Taylor, Carlos Barrios, Leandro Brust, Costa Fabiano, de Freitas Junior Ruffo, Roberto Hegg, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Danielle Charpentier, Ferrario Cristiano, Xinni Song, Yu Joanne, Alejandro Acevedo, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Eduardo Yañez, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Bohuslav Melichar, Katarína Petráková, Prausova Jana, Vesna Glavicic, Jakobsen Erik, Jensen Jeanette, Søren Linnet, Tamás Lörincz, Bonnefoi Herve, Isabelle Desmoulins, Goncalves Anthony, Hardy-Bessard Anne-Claire, Luís Teixeira, Blohmer Jens-Uwe, Fasching Peter, Dirk Forstmeyer, Nadia Harbeck, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Sibylle Loibl, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Pauline Wimberger, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Peter Arkosy, Tibor Csőszi, Zsuzsanna Kahán, Landherr László, Mahr Karoly, Gábor Rubovszky, Crown John, Kelly Catherine, O'Reilly Seamus, Saverio Cinieri, DAlessio Antonietta, Ricevuto Enrico, Tomoyuki Aruga, Takaaki Fujii, Inoue Kenichi and 127 more - The Lancet 2020 cited by 1,800

  7. Palbociclib and Letrozole in Advanced Breast Cancer

    Authors: Richard S. Finn, Miguel Martín, Hope S. Rugo, Stephen E. Jones, Seock‐Ah Im, Karen A. Gelmon, Nadia Harbeck, Oleg Lipatov, Janice M. Walshe, Stacy Moulder, Eric Gauthier, Dongrui R. Lu, Sophia Randolph, Véronique Dièras, Dennis J. Slamon - New England Journal of Medicine 2016 cited by 2,948

  8. Breast cancer

    Authors: Nadia Harbeck, Michael Gnant - The Lancet 2016 cited by 2,305

  9. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

    Authors: Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Jane Yuet Ching Hui, Nadia Harbeck - The Lancet 2020 cited by 1,060

  10. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Sibylle Loibl, Fabrice André, Thomas Bachelot, Carlos H. Barrios, Jonas Bergh, Harold J. Burstein, Maria João Cardoso, Lisa A. Carey, Shaheenah Dawood, Lucia Del Mastro, Carsten Denkert, Eva Maria Fallenberg, Prudence A. Francis, H. Gamal‐El‐Din, Karen A. Gelmon, Charles E. Geyer, Michael Gnant, Valentina Guarneri, Sudeep Gupta, Sung‐Bae Kim, David Krug, Miguel Martín, Icro Meattini, Monica Morrow, Wolfgang Janni, Shani Paluch–Shimon, Ann H. Partridge, Philip Poortmans, Lajos Pusztai, Meredith M. Regan, Joseph A. Sparano, Tanja Španić, Sandra M. Swain, Sergei Tjulandin, Masakazu Toi, Dario Trapani, Andrew Tutt, B. Xu, Giuseppe Curigliano, Nadia Harbeck - Annals of Oncology 2023 cited by 844

  11. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    Authors: Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun‐Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, İrfan Çiçin, Sara M. Tolaney, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Marı́a Jesús Muñoz, Belén San Antonio, Valérie André, Nadia Harbeck, Miguel Martín - The Lancet Oncology 2022 cited by 566

  12. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Authors: Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus, Giuseppe Curigliano, Matti Aapro, Fabrice André, C.H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Frances Boyle, Maria João Cardoso, L.A. Carey, Javier Cortés, Nagi S. El Saghir, Mona Elzayat, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Karen A. Gelmon, Joseph Gligorov, Renate Haidinger, Nadia Harbeck, Xin Hu, Bella Kaufman, Rajneesh Kaur, Belinda E. Kiely, S.-B. Kim, NU Lin, Shirley Mertz, Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, A. Prat, Frédérique Penault‐Llorca, Hope S. Rugo, G. W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer - Annals of Oncology 2020 cited by 1,356

  13. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Authors: Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortés, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, Priya Rastogi - Journal of Clinical Oncology 2020 cited by 986

  14. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 cited by 1,822

  15. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    Authors: Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer - Annals of Oncology 2016 cited by 2,062

  16. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Authors: Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, William P. Weber, Philip Poortmans, Meredith M. Regan, H.-J. Senn, Eric P. Winer, Michael Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel Morales, Sara Y. Brucker, Harold J. Burstein, David Cameron, Fátima Cardoso, Lisa A. Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence A. Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 cited by 803

  17. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Authors: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 cited by 1,293

  18. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  19. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Authors: Debu Tripathy, Seock‐Ah Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, Louis W.C. Chow, Joohyuk Sohn, Keun Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung Hae Jung, Govind Babu, Paul Wheatley‐Price, Michelino De Laurentiis, Young‐Hyuck Im, Sherko Küemmel, Nagi S. El-Saghir, Mei-Ching Liu, Gary P. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu - The Lancet Oncology 2018 cited by 1,011

  20. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 cited by 1,586

  21. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Authors: Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fábio Franke, Louis W.C. Chow, Joohyuk Sohn, Keun-Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung-Hae Jung, Arunava Chakravartty, Gareth Hughes, Ioannis Gounaris, Karen Rodriguez-Lorenc, Tetiana Taran, Sara A. Hurvitz, Debu Tripathy - New England Journal of Medicine 2019 cited by 1,021

  22. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

    Authors: Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés - The Lancet Oncology 2021 cited by 493

  23. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Heather L. McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock‐Ah Im, Michael Untch, Peter A. Fasching, Marie‐Ange Mouret‐Reynier, Theodoros Foukakis, Marta Ferreira, Fátima Cardoso, Xuan Zhou, Vassiliki Karantza, Konstantinos Tryfonidis, Gursel Aktan, Joyce O’Shaughnessy - New England Journal of Medicine 2024 cited by 419

  24. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    Authors: Alan S. Coates, Eric P. Winer, Aron Goldhirsch, Richard D. Gelber, Michael Gnant, Martine Piccart, Beat Thürlimann, H.-J. Senn, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Viviana Galimberti, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Jens Huober, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C. Kent Osborne, Ann H. Partridge, Lorena de la Peña, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gϋnter von Minckwitz, Toru Watanabe, Timothy J. Whelan, Eric P. Winer, Binghe Xu - Annals of Oncology 2015 cited by 1,837